[英语，研究]乙型肝炎和助推剂量需要

StephenW

<http://cid.oxfordjournals.org/content/53/1/68.abstract?etoc>

Clinical Infectious Diseases
Volume53, Issue1
Pp. 68-75.

Hepatitis B and the Need for a Booster Dose

Stanley Plotkin, Section Editor
+ Author Affiliations
Elke Leuridan and
Pierre Van Damme
+ Author Affiliations
Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease
Institute, World Health Organziation Collaborating Centre for the
Prevention and Control of Infectious Diseases, Faculty of Medicine,
University of Antwerp, Edegem, Belgium Correspondence: Elke Leuridan, MD,
Vaccine and Infectious Disease Institute, University of Antwerp,
Universiteitsplein 1,Antwerp, B-2610, Belgium ([email protected]).

Abstract
After several decades of vaccination against hepatitis B virus in newborns,
infants, adolescents, and adults, the question remains whether a booster
dose is ever needed. Long-term protection is most commonly measured through
4 methods: the anamnestic response after administration of a booster dose,
infection rate in vaccinated populations, in vitro B and T cell activity
testing, and seroepidemiological studies. Long-term protection is present
despite a decrease in anti-hepatitis B surface antibodies over time. The
exact mechanism of long-term protection, however, is not yet fully
understood. There is no need for boosters in immunologically potent persons
as long as a full course was adequately administered that respected the
recommended timelines, as evidenced by studies conducted up to 20 years
after the original immunization course. However, a booster dose should be
planned for immunocompromised patients, based on serological monitoring.

Received December 28, 2010.
Accepted March 29, 2011.

© The Author 2011. Published by Oxford University Press on behalf of the
Infectious Diseases Society of America. All rights reserved. For
Permissions, please e-mail: [email protected].

StephenW

临床传染病
Volume53，Issue1
页。 68-75。

乙型肝炎和助推剂量的需要

斯坦利普洛特金，编辑组
+作者机构
埃尔克Leuridan和
皮埃尔凡丹梅
+作者机构
中心的预防接种，疫苗和传染病评价
研究所，世界卫生组织Organziation合作为中心
防治传染性疾病，医学系的控制，
安特卫普大学，Edegem，比利时通讯：埃尔克Leuridan医师
疫苗和传染性疾病研究所，安特卫普大学，
Universiteitsplein1，安特卫普的B -2610，比利时（elke.leuridan@ ua.ac.be）。

摘要
经过对新生儿乙肝疫苗接种病毒几十年来，
婴幼儿，青少年和成年人，问题是，是否一个助推器
剂量是永远需要的。长期保护是最常用的测量通过
4种方法：后的一个助推器剂量给药回忆应答，
在接种疫苗的人群感染率，体外B和T细胞活性
测试和血清流行病学研究。长期存在的保护
尽管在抗乙肝表面抗体随着时间的推移下降。该
长期保护的确切机制，但尚未完全
理解。没有强有力的助推器，人需要在免疫
只要管理的全过程得到了充分的尊重
建议的时间表，如进行长达20年的研究证明
后，原来的免疫过程。然而，剂量应助推器
计划免疫功能低下的患者血清学监测为基础。

收到二零一零年十二月二十八日。
接受2011年3月29日。

©2011年的作者。由牛津大学出版社出版的代
美国传染病协会。保留所有权利。对于
权限，请E - mail：journals.permissions@ oup.com。

rinusyida